Biotech Startup Funding Deals Tracked Through May 2025
Biotech fundraising in early 2025 is being catalogued deal by deal — and the aggregate picture tells you where capital conviction is actually landing, not where press releases say it is.
Explanation
This is an incremental data signal: a running compilation of biotechnology startup funding rounds closed up to May 2025. It tracks startup names, dollar amounts raised, round types (Seed, Series A, B, etc.), and the lead investors behind each deal.
Why it matters now: early-year funding patterns are a leading indicator of which therapeutic areas, platforms, and business models the smart money is backing before clinical proof points arrive. If you wait for Phase 2 readouts to form a view, you're already late.
The dataset is still being populated — the source note flags a variable start date, meaning coverage may be uneven across Q1 and Q2. That's worth keeping in mind before drawing hard conclusions from apparent gaps or clusters.
What to watch in the numbers: round size inflation (are Series A tickets creeping toward what Series B used to look like?), investor syndicate overlap (the same five funds co-leading everything is a concentration risk, not a validation signal), and which sub-sectors — GLP-1 adjacents, RNA therapeutics, AI-driven drug discovery — are pulling disproportionate capital.
The "so what" for today: if you're tracking competitive landscape, partnership targets, or valuation benchmarks, this kind of deal-flow map is the raw material. Incremental as it is, each new entry updates the picture. Watch for the May 2025 cutoff to reveal whether Q1 momentum held or whether macro rate anxiety clipped deal velocity into spring.
This signal is a structured deal-flow tracker for biotech venture activity through May 2025 — covering round type, capital raised, lead and co-investors, and startup identity. The source flags a variable beginning date, which introduces survivorship and coverage bias risks that any downstream analysis needs to account for explicitly.
Mechanistically, early-year biotech funding data is useful precisely because it precedes most clinical catalysts. Capital allocation at Seed through Series B reflects thesis-level conviction — platform bets, modality preferences, founder networks — rather than de-risked asset value. Aggregating it lets you reverse-engineer where top-tier funds are building position before the market prices in the science.
Prior context matters here: 2023-2024 saw a bifurcated biotech funding environment — mega-rounds for AI-drug-discovery platforms (Isomorphic, Recursion, Insilico) alongside a drought for mid-stage companies without near-term catalysts. Whether 2025 is continuing that bifurcation or reverting toward broader deal distribution is the core question this dataset can answer.
Key variables to stress-test as data fills in: (1) median round size by stage vs. 2023-2024 comps — are valuations resetting or still elevated? (2) geographic distribution — is Europe closing the gap with US deal count, or is capital still concentrating in Boston/Bay Area? (3) investor debut rate — new entrants to biotech VC signal either opportunism or genuine thesis expansion. (4) therapeutic area clustering — outsized GLP-1, CNS, or longevity concentration would confirm or challenge the narrative of a diversifying pipeline.
Open question and falsifier: if the May 2025 cutoff shows deal count and aggregate capital below H1 2024 levels, the "biotech recovery" narrative that dominated late 2024 commentary needs a hard revision. That's the number to watch.
Reality meter
Why this score?
Trust Layer Score basis
A detailed evidence breakdown is being added. For now, the score basis is the source list below and the reality meter above.
- 46 sources on file
- Avg trust 42/100
- Trust 40–95/100
Time horizon
Community read
Glossary
- deal-flow tracker
- A systematic record or database that monitors and catalogs investment transactions and funding rounds, used to identify patterns and trends in capital allocation across a sector.
- survivorship bias
- A statistical error that occurs when analyzing only successful or surviving entities while ignoring those that failed or were excluded, leading to skewed conclusions about overall performance or trends.
- clinical catalysts
- Significant milestones or events in drug development—such as trial results, regulatory approvals, or FDA decisions—that can materially affect a company's valuation and investor perception.
- Series B
- A later-stage venture capital funding round that typically follows Series A, used by growing companies to expand operations and market reach before approaching profitability or exit.
- AI-drug-discovery platforms
- Software and computational systems that use artificial intelligence to accelerate the identification and design of new drug candidates, reducing traditional development timelines and costs.
- therapeutic area
- A specific category or disease domain within medicine and drug development, such as oncology, cardiology, or neurology, used to segment and analyze pharmaceutical pipelines.
What's your read?
Your read shapes future topic weighting.
Your vote feeds topic weights, community direction and future prioritisation. Open community direction
Sources
- Tier 3 Biotechnology Startup Funding 2025-2026
- Tier 3 Biotechnology News -- ScienceDaily
- Tier 3 Colossal Biosciences announces ‘de-extinction’ plan for African bluebuck | CNN
- Tier 3 Clarkson University Researchers Contribute to Breakthrough Biosensor Technology Published in Nature Biotechnology | Clarkson University
- Tier 3 Biotech and Pharma Industry News | BioPharma Dive
- Tier 3 ScienceDaily: Your source for the latest research news
- Tier 3 Fierce Biotech News & Reports
- Tier 1 Nature Biotechnology
- Tier 3 2024 in science - Wikipedia
- Tier 3 Top Biotech Startups 2026: An Analysis of Emerging Trends | IntuitionLabs
- Tier 3 Study: CRISPR gene editing leads to improvements in vision for people with inherited blindness | Ophthalmology Times - Clinical Insights for Eye Specialists
- Tier 3 A one-time treatment tweaked their genes — and lowered their cholesterol
- Tier 3 Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing - Intellia Therapeutics
- Tier 3 Potential Cure for HIV from CRISPR Gene Editing in Phase 1/2 Clinical Trial | Contagion Live
- Tier 3 Milestone for Crispr: First-of-Its-Kind Gene Editing Treatment Successfully Passes Clinical Trial
- Tier 3 CRISPR gene editing - Wikipedia
- Tier 3 Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder | BioPharma Dive
- Tier 3 Discovery broadens scope of use of CRISPR gene editing | ScienceDaily
- Tier 3 Scientists just made CRISPR three times more effective | ScienceDaily
- Tier 3 Synthetic Biology Market Size, Share, Industry Growth 2035
- Tier 3 Synthetic Biology Market Size, Share & Growth Trends 2035
- Tier 3 Flagship Pioneering Launches Serif Biomedicines to Establish Modified DNA as a New Biotechnology
- Tier 3 SynbiTECH 2026 | The Must-Attend Synthetic Biology Conference
- Tier 3 2026 Synthetic Biology: Engineering, Evolution, & Design (SEED) | AIChE
- Tier 3 Synthetic Biology Market worth $31.52 billion in 2029 | Press Releases | reformer.com
- Tier 3 Synthetic Biology Market Analysis 2026-2031: Genome Engineering Accounts for 33.21% Share, with Asia-Pacific as the Fastest-Growing Region, Says Mordor Intelligence
- Tier 3 Global DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical Applications
- Tier 3 North America Gene Synthesis Market Outlook 2026-2034
- Tier 3 Synthetic Biology Product Market is Going to Boom | Amyris , Zymergen
- Tier 3 List of Funded Biotech Startups (2026) - Fundraise Insider
- Tier 3 Early-stage funding slumps toward post-pandemic low, piling more pressure on biotech startups
- Tier 3 The Week’s 10 Biggest Funding Rounds: SiFive Leads With $400M For Custom Chip Designs As Aviation, Biotech And Defense Startups Also Raise Big
- Tier 3 1,200+ Funded Biotech Startups 2026 | Verified Contacts
- Tier 3 Biotech Valuation Benchmarks for Series A and B in 2026
- Tier 3 The Week’s 10 Biggest Funding Rounds: AI, Autonomy And Biotech Top The Ranks
- Tier 3 Jeito Capital, prominent biotech investor, raises $1.2B for next fund | BioPharma Dive
- Tier 3 Stanford's James Zou targets $1B valuation for AI physiology startup backed by Nature-published research and FDA-cleared cardiac AI
- Tier 3 DNA origami vaccines could be the next leap beyond mRNA | ScienceDaily
- Tier 1 Engineered cells as programmable mRNA delivery vehicles | Nature Reviews Bioengineering
- Tier 3 AI, CRISPR, and mRNA Driving Biotech’s Smartest Decade Yet | BioPharm International
- Tier 3 New Research Challenges Understanding of mRNA Vaccines and Establishes Innovative Way to Make Them More Effective | Mount Sinai - New York
- Tier 3 mRNA Delivery Technology Landscape 2026 — PatSnap Eureka | PatSnap
- Tier 3 Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy | Cellular Oncology | Springer Nature Link
- Tier 3 After a year of turmoil, cancer researchers see promising signs for mRNA vaccines | CNN
- Tier 3 mRNA Therapeutics Market Size to Hit USD 83.49 Billion by 2035 - BioSpace
- Tier 3 Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy - PMC
Optional Submit a prediction Optional: add your prediction on the core question if you like.
Prediction
Will total biotech startup funding tracked through May 2025 exceed the H1 2024 aggregate in both deal count and total capital raised?